Search results for "Vaccinations"
Treatment for high-risk COVID-19 patients, vaccine news, research on health messaging
An industry-funded study found benefit with bamlanivimab plus etesevimab for high-risk ambulatory COVID-19 patients, the FDA noted a possible increased risk for Guillain-Barré syndrome with the Johnson & Johnson (Janssen) vaccine, and two studies looked at COVID-19 messaging for minority populations.
https://immattersacp.org/weekly/archives/2021/07/20/1.htm
20 Jul 2021
Studies look at COVID-19 vaccine boosters; ACP, Annals forum tackles challenging clinical questions
Two Israeli studies showed that vaccine boosters reduced rates of infection and severe disease. Experts gathered for the seventh ACP and Annals of Internal Medicine virtual forum on COVID-19. The FDA authorized a monoclonal antibody for pre-exposure prophylaxis in certain patients.
https://immattersacp.org/weekly/archives/2021/12/14/1.htm
14 Dec 2021
One-fifth of COVID-19 patients taking nirmatrelvir-ritonavir had viral rebound
A small observational study of ambulatory patients with COVID-19 found that 1.8% of untreated patients tested positive again after testing negative, compared to 20.8% of those who took five days of nirmatrelvir-ritonavir.
https://immattersacp.org/weekly/archives/2023/11/14/4.htm
14 Nov 2023
Latest on COVID-19 and bamlanivimab, vaccines, long-term effects
Bamlanivimab reduced viral load in mild to moderate cases when combined with etesevimab, new vaccine recommendations, research, and educational resources were released, and two studies provided longer-term data on patients who had COVID-19.
https://immattersacp.org/weekly/archives/2021/01/26/1.htm
26 Jan 2021
New vaccine authorization and data, NIH on antibody treatment and ‘long COVID’
The Johnson & Johnson COVID-19 vaccine got an emergency use authorization, and an Israeli study provided more data on the Pfizer vaccine. The NIH recommended an antibody combo for outpatients and named long-term symptoms as post-acute sequelae of SARS-CoV-2 (PASC).
https://immattersacp.org/weekly/archives/2021/03/02/1.htm
2 Mar 2021
Clot concerns with adenovirus COVID-19 vaccines, antibody treatment recommendations and data
Based on reports of cerebral venous sinus thrombosis with the Johnson & Johnson (Janssen) COVID-19 vaccine, federal officials recommended a pause in its use, which will be reconsidered on April 23. The NIH updated its recommendations on monoclonal antibody treatments for outpatients.
https://immattersacp.org/weekly/archives/2021/04/20/1.htm
20 Apr 2021
More clarity on myocarditis with mRNA COVID-19 vaccines
The classic presentation for COVID-19 vaccine-associated myocarditis is chest pain one to seven days after vaccination, with a median time of three days after vaccination, particularly after the second dose.
https://immattersacp.org/archives/2023/02/more-clarity-on-myocarditis-with-mrna-covid-19-vaccines.htm
1 Feb 2023
CDC issues interim guidance on measles infection control and prevention in health care
New government guidance covers what is acceptable evidence of immunity to measles and how to respond if health care personnel are exposed to the disease.
https://immattersacp.org/weekly/archives/2019/07/30/4.htm
30 Jul 2019
Concomitant influenza infection associated with worse in-hospital outcomes in heart failure patients
Rates of in-hospital mortality, acute respiratory failure with and without mechanical ventilation, and acute kidney injury with and without dialysis were significantly higher in patients admitted with heart failure and influenza infection compared to admissions for heart failure alone.
https://immattersacp.org/weekly/archives/2019/01/08/4.htm
8 Jan 2019
The push toward a COVID-19 vaccine
As America closes in on a vaccine for COVID-19, experts focus on which ones will work best, if at all, how to ramp up production, and how to fairly administer millions of doses.
https://immattersacp.org/archives/2020/11/the-push-toward-a-covid-19-vaccine.htm
1 Nov 2020